The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giovarelli, M.
Right arrow Articles by De Giovanni, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giovarelli, M.
Right arrow Articles by De Giovanni, C.

The Journal of Immunology, Vol 155, Issue 6 3112-3123, Copyright © 1995 by American Association of Immunologists

ARTICLES

Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory

M Giovarelli, P Musiani, A Modesti, P Dellabona, G Casorati, A Allione, M Consalvo, F Cavallo, F di Pierro and C De Giovanni
CNR Center for Immunogenetics and Experimental Oncology, University of Turin, Italy.

The cDNA coding for mouse IL-10 (mIL-10) was transduced into the parental cells of a spontaneous adenocarcinoma of BALB/c mice (TSA-pc), and clones secreting small, medium, and large quantities of IL-10 were selected. In vivo, both low and high producer clones do not display an enhanced ability to grow in H-2 and non-H-2 incompatible mice. Instead, the intensity of their rejection increases in function of the amount of mIL-10 released. After an initial growth period in syngeneic mice, high producer clones undergo complete rejection due to the combined action of CD8+ lymphocytes, NK cells, and neutrophils. After this rejection, mice are immune to a subsequent challenge with TSA-pc. This memory rests on a strong lytic activity of CD8+ CTL and granulocytes. Following the rejection, mice also develop anti-TSA Ab that guide the granulocytes in TSA-pc memory reaction. A direct comparison shows that although TSA clones engineered to release IL-2 activate CTL and no anti- TSA Ab, those engineered to release IL-4 activate a strong Ab response but not CTL. The kind of cytokine released by the tumors appears to determine the type of response. However, IL-10 high producer cells do not deviate the immune memory, neither toward a Th1 nor a Th2. Both the CTL activity and the Ab responses induced by IL-10 high producer cells are the strongest so far observed in the TSA system.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
L. M. Montuenga and R. Pio
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10
Eur. Respir. J., October 1, 2007; 30(4): 608 - 610.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Mortara, P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F. A. Procopio, A. Comes, L. Zardi, S. Ferrini, and R. S. Accolla
CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory.
Clin. Cancer Res., June 1, 2006; 12(11): 3435 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mocellin, F. M. Marincola, and H. A. Young
Interleukin-10 and the immune response against cancer: a counterpoint
J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. V. Lopez, S. K. Adris, A. I. Bravo, Y. Chernajovsky, and O. L. Podhajcer
IL-12 and IL-10 Expression Synergize to Induce the Immune-Mediated Eradication of Established Colon and Mammary Tumors and Lung Metastasis
J. Immunol., November 1, 2005; 175(9): 5885 - 5894.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Kurte, M. Lopez, A. Aguirre, A. Escobar, J. C. Aguillon, J. Charo, C. G. Larsen, R. Kiessling, and F. Salazar-Onfray
A Synthetic Peptide Homologous to Functional Domain of Human IL-10 Down-Regulates Expression of MHC Class I and Transporter Associated with Antigen Processing 1/2 in Human Melanoma Cells
J. Immunol., August 1, 2004; 173(3): 1731 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Kalechman, U. Gafter, T. Weinstein, A. Chagnac, I. Freidkin, A. Tobar, M. Albeck, and B. Sredni
Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis: ASSOCIATION WITH DEPHOSPHORYLATION OF STAT3
J. Biol. Chem., June 4, 2004; 279(23): 24724 - 24732.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Cappello, F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P.-L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli, et al.
LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/neu Transgenic BALB/c Mice
Cancer Res., May 15, 2003; 63(10): 2518 - 2525.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-C. Soria, C. Moon, B. L. Kemp, D. D. Liu, L. Feng, X. Tang, Y.-S. Chang, L. Mao, and F. R. Khuri
Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res., May 1, 2003; 9(5): 1785 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
I Y Rosenblum and A D Dayan
Carcinogenicity testing of IL-10: principles and practicalities
Human and Experimental Toxicology, July 1, 2002; 21(7): 347 - 358.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
R. Dorsey, N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton
Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN-{gamma}
Cancer Res., May 1, 2002; 62(9): 2606 - 2610.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Koido, Y. Tanaka, D. Chen, D. Kufe, and J. Gong
The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice
J. Immunol., March 1, 2002; 168(5): 2111 - 2117.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. M. Segal, D. D. Glass, and E. M. Shevach
Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection
J. Immunol., January 1, 2002; 168(1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Role of Effector Cell-Derived IL-4, IL-5, and Perforin in Early and Late Stages of Type 2 CD8 Effector Cell-Mediated Tumor Rejection
J. Immunol., July 1, 2001; 167(1): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Di Carlo, G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani
The intriguing role of polymorphonuclear neutrophils in antitumor reactions
Blood, January 15, 2001; 97(2): 339 - 345.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Rovero, A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, et al.
DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice
J. Immunol., November 1, 2000; 165(9): 5133 - 5142.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Grimm, C. M. Smid, J. J. Lee, C.-H. Tseng, O. Eton, and A. C. Buzaid
Unexpected Cytokines in Serum of Malignant Melanoma Patients during Sequential Biochemotherapy
Clin. Cancer Res., October 1, 2000; 6(10): 3895 - 3903.
[Abstract] [Full Text]

Home page
 BloodHome page
L. Cervenak, L. Morbidelli, D. Donati, S. Donnini, T. Kambayashi, J. L. Wilson, H. Axelson, E. Castanos-Velez, H.-G. Ljunggren, R. D. W. Malefyt, et al.
Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10
Blood, October 1, 2000; 96(7): 2568 - 2573.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. D. Santin, P. L. Hermonat, A. Ravaggi, S. Bellone, S. Pecorelli, J. J. Roman, G. P. Parham, and M. J. Cannon
Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes
J. Virol., May 15, 2000; 74(10): 4729 - 4737.
[Abstract] [Full Text]

Home page
 J. Gen. Virol.Home page
M. C. López and M. A. Stanley
Cytokine profile of draining lymph node lymphocytes in mice grafted with syngeneic keratinocytes expressing human papillomavirus type 16 E7 protein
J. Gen. Virol., May 1, 2000; 81(5): 1175 - 1182.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
M. Giovarelli, P. Cappello, G. Forni, T. Salcedo, P. A. Moore, D. W. LeFleur, B. Nardelli, E. D. Carlo, P.-L. Lollini, S. Ruben, et al.
Tumor Rejection and Immune Memory Elicited by Locally Released LEC Chemokine Are Associated with an Impressive Recruitment of APCs, Lymphocytes, and Granulocytes
J. Immunol., March 15, 2000; 164(6): 3200 - 3206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Sharma, M. Stolina, Y. Lin, B. Gardner, P. W. Miller, M. Kronenberg, and S. M. Dubinett
T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function
J. Immunol., November 1, 1999; 163(9): 5020 - 5028.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Bellone, A. Turletti, E. Artusio, K. Mareschi, A. Carbone, D. Tibaudi, A. Robecchi, G. Emanuelli, and U. Rodeck
Tumor-Associated Transforming Growth Factor-{beta} and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients
Am. J. Pathol., August 1, 1999; 155(2): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Seo, Y. Tokura, M. Takigawa, and K. Egawa
Depletion of IL-10- and TGF-{beta}-Producing Regulatory {gamma}{delta} T Cells by Administering a Daunomycin-Conjugated Specific Monoclonal Antibody in Early Tumor Lesions Augments the Activity of CTLs and NK Cells
J. Immunol., July 1, 1999; 163(1): 242 - 249.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Bronte, D. B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu, and N. P. Restifo
Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
J. Immunol., May 15, 1999; 162(10): 5728 - 5737.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. G. Chakraborty, L. Li, J. R. Sporn, S. H. Kurtzman, M. T. Ergin, and B. Mukherji
Emergence of Regulatory CD4+ T Cell Response to Repetitive Stimulation with Antigen-Presenting Cells In Vitro: Implications in Designing Antigen-Presenting Cell-Based Tumor Vaccines
J. Immunol., May 1, 1999; 162(9): 5576 - 5583.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Steinbrink, H. Jonuleit, G. Muller, G. Schuler, J. Knop, and A. H. Enk
Interleukin-10-Treated Human Dendritic Cells Induce a Melanoma-Antigen-Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells
Blood, March 1, 1999; 93(5): 1634 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. K. Halak, H. C. Maguire Jr., and E. C. Lattime
Tumor-induced Interleukin-10 Inhibits Type 1 Immune Responses Directed at a Tumor Antigen As Well As a Non-Tumor Antigen Present at the Tumor Site
Cancer Res., February 1, 1999; 59(4): 911 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Cavallo, E. D. Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni
Immune Events Associated with the Cure of Established Tumors and Spontaneous Metastases by Local and Systemic Interleukin 12
Cancer Res., January 1, 1999; 59(2): 414 - 421.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.